Download docx - · Web view# Searches. Results. 1. exp Kidney Failure, Chronic/ 122462. 2. exp end stage renal disease/ 87207. 3 ("chronic kidney failure" or "chronic renal failure" or "end

Table of ContentsSEARCH STRATEGY................................................................................................................................................................................................3

Table I: Characteristics of the included studies:...........................................................................................................................................................8

Table II: Outcomes (rate, 95% confidence interval) per vascular access type:..........................................................................................................27

Table III: Outcomes (rate, 95% confidence interval) per subgroups for each vascular access type:..........................................................................28

III.1: Arteriovenous fistula (AVF), unspecified location:......................................................................................................................................28

III.2: Upper arm AVF:........................................................................................................................................................................................... 30

III.3: Brachial- Basilic fistula:...............................................................................................................................................................................30

III.4: Brachial-brachial fistula:...............................................................................................................................................................................31

III.5: Brachial-Cephalic fistula:.............................................................................................................................................................................32

III.6: Forearm AVF:............................................................................................................................................................................................... 33

III.7: Radiocephalic fistula:....................................................................................................................................................................................34

III.8: Forearm basilic fistula:.................................................................................................................................................................................37

III.9: Lower extremity fistula:................................................................................................................................................................................37

III.10: Arteriovenous graft (AVG), unspecified location:......................................................................................................................................38

III.11: Upper arm graft:..........................................................................................................................................................................................39

III.12: Forearm graft:............................................................................................................................................................................................. 40

III.13: Axillary-Axillary graft:...............................................................................................................................................................................40

III.14: Lower extremity graft:................................................................................................................................................................................41

III.15: Tunneled cuffed catheter, unspecified location:..........................................................................................................................................41

III.16: Tunneled cuffed IJ/subclavian PermCath:...................................................................................................................................................42

1

III.17: Hybrid graft and catheter (HeRO):..............................................................................................................................................................42

Table IV: Average days to maturation:......................................................................................................................................................................44

Table V: Summary results of meta-analysis of included comparative studies per access types:................................................................................45

V.1: AVF, unspecified location:............................................................................................................................................................................45

V.2: AVF, unspecified location VS. Tunneled cuffed catheters, unspecified location:..........................................................................................47

V.3: Forearm AVF VS. Upper-arm AVF:..............................................................................................................................................................49

V.4: Tunneled cuffed catheters, unspecified location VS. AVF, unspecified location:.........................................................................................49

V.5: AVG, unspecified location VS. AVF, unspecified location:..........................................................................................................................50

V.6: AVG, unspecified location VS. Tunneled cuffed catheters, unspecified location:.........................................................................................51

References:................................................................................................................................................................................................................ 54

2

SEARCH STRATEGYOvid

Database(s): Embase 1988 to 2014 Week 45, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials October 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2014 Search Strategy:# Searches Results

1 exp Kidney Failure, Chronic/ 1224622 exp end stage renal disease/ 87207

3

("chronic kidney failure" or "chronic renal failure" or "end stage kidney disease" or "end stage kidney failure" or "end stage renal disease" or "end stage renal dysfunction" or "end stage renal failure" or "end stage renal impairment" or "end stage renal insufficiency" or "end-stage kidney disease" or "end-stage renal disease" or "end-stage renal failure" or ESRD or "stage 5 kidney disease" or "stage 5 renal disease").mp.

132847

4 or/1-3 1826145 exp hemodialysis/ 1613006 exp Renal Dialysis/ 208945

7

((dialys* adj (center* or centre*)) or "acetate free biofiltration*" or "blood dialys*" or "extracorporeal blood cleansing" or "extracorporeal dialys*" or haemodiafiltration* or haemodialys* or haemorenodialys* or haemotrialysate* or hemodiafiltration* or hemodialys* or hemorenodialys* or hemotrialysate* or "kidney dialys*" or "peritoneal dialys*" or "renal dialys*").mp.

226829

8 or/5-7 2452299 (longterm or "long-term" or chronic*).mp. 329560810 8 and 9 111324

11

(((dialys* or "acetate free biofiltration*" or "extracorporeal blood cleansing" or haemodiafiltration* or haemodialys* or haemorenodialys* or haemotrialysate* or hemodiafiltration* or hemodialys* or hemorenodialys* or hemotrialysate* or site or route or fistula* or catheter*) adj3 access*) or "Atrial graft*" or "Axillary axillary graft*" or "Brachial-basilic*" or "Brachial-brachial" or "Brachial-cephalic*" or "Cimino-radialcephalic*" or "Forearm basilic*" or "Forearm loop graft*" or HeRO or "Lower extremity fistula*" or "Lower extremity graft*" or permacath* or "perma-cath*" or "Upper arm graft*").mp.

24338

12 4 and 10 and 11 236913 exp evidence based medicine/ 733513

3

14 exp meta analysis/ 13886115 exp Meta-Analysis as Topic/ 3071716 exp "systematic review"/ 8137417 exp Guideline/ or exp Practice Guideline/ 34788018 exp controlled study/ 455482919 exp Randomized Controlled Trial/ 73840520 exp triple blind procedure/ 7521 exp Double-Blind Method/ 34681922 exp Single-Blind Method/ 5213723 exp latin square design/ 27724 exp Placebos/ 27105925 exp Placebo Effect/ 740526 exp comparative study/ 249376727 exp Cross-Sectional Studies/ 31950728 exp Cross-Over Studies/ 10274729 exp Cohort Studies/ 172554830 exp longitudinal study/ 109148331 exp retrospective study/ 88536832 exp prospective study/ 71714733 exp population research/ 6868634 exp observational study/ 6879735 exp clinical trial/ 175770636 clinical study/ 5504337 exp Evaluation Studies/ 21552138 exp Evaluation Studies as Topic/ 115944739 exp quantitative study/ 600740 exp validation studies/ 11699041 exp experimental study/ 1509842 exp quasi experimental study/ 212543 in vivo study/ 192702

4

44 exp panel study/ 38245 exp Pilot Projects/ 17501946 exp pilot study/ 17501947 exp prevention study/ 219248 exp replication study/ 98549 exp theoretical study/ 142630950 exp Feasibility Studies/ 10207151 exp trend study/ 1161552 exp correlational study/ 1187153 exp case-control studies/ 80839354 exp confidence interval/ 12491355 exp regression analysis/ 58996756 exp proportional hazards model/ 9935557 exp multivariate analysis/ 35262058 ((evidence adj based) or (outcome* adj (research or assessment*)) or (meta adj analys*) or (systematic* adj3 review*) or

guideline* or (doubl* adj blind*) or (doubl* adj mask*) or (singl* adj blind*) or (singl* adj mask*) or (tripl* adj blind*) or (tripl* adj mask*) or (trebl* adj blind*) or (trebl* adj mask*) or "latin square" or placebo* or nocebo* or random* or control* or multivariate or "comparative study" or "comparative survey" or "comparative analysis" or compar* or (intervention* adj2 study) or (intervention* adj2 trial) or "cross-sectional study" or "cross-sectional analysis" or "cross-sectional survey" or "cross-sectional design" or "prevalence study" or "prevalence analysis" or "prevalence survey" or "disease frequency study" or "disease frequency analysis" or "disease frequency survey" or crossover or "cross-over" or cohort* or "longitudinal study" or "longitudinal survey" or "longitudinal analysis" or "longitudinal evaluation" or longitudinal* or ((retrospective or "ex post facto") adj3 (study or survey or analysis or design)) or retrospectiv* or "prospective study" or "prospective survey" or "prospective analysis" or prospectiv* or "population study" or "population survey" or "population analysis" or "population research" or "concurrent study" or "concurrent survey" or "concurrent analysis" or "incidence study" or "incidence survey" or "incidence analysis" or (("follow-up" or followup) adj (stud* or survey or analysis)) or ((observation or observational) adj (study or survey or analysis)) or "case study" or "case series" or "clinical series" or "case studies" or "clinical study" or "clinical trial" or "evaluation study" or "evaluation survey" or "evaluation analysis" or "quantitative study" or "quantitative analys*" or "numerical study" or "validation study" or "validation survey" or "validation analysis" or "experimental study" or "experimental analysis" or "quasi experimental study" or "quasi experimental analysis" or "quasiexperimental study" or "quasiexperimental analysis" or "field study" or "field survey" or "field analysis" or "in vivo study" or "in vivo analysis" or "panel study" or "panel survey" or "panel

22826290

5

analysis" or "pilot study" or "pilot survey" or "pilot analysis" or "pilot project" or ((prevention or preventive) adj3 (trial or study or analysis or survey)) or "replication study" or "replication analysis " or "replication trial" or "theoretical study" or "theoretical analysis " or "feasibility study" or "feasibility analysis" or "trend study" or "trend survey" or "trend analysis" or ((correlation* adj2 study) or (correlation* adj2 analys*)) or "case control study" or "case base study" or "case referrent study" or "case referent study" or "case referent study" or "case compeer study" or "case comparison study" or "matched case control" or "multicenter study" or "multi-center study" or study or trial or pilot or "odds ratio" or "confidence interval" or "regression analysis" or "least square" or "least squares" or (hazard* adj (model or analys* or regression)) or "Cox model" or "Cox multivariate analyses" or "Cox multivariate analysis" or "Cox regression" or "Cox survival analyses" or "Cox survival analysis" or "Cox survival model" or "change analysis" or ((study or trial or random* or control*) and compar*)).mp,pt.

59 or/13-58 2372570660 12 and 59 169761 from 12 keep 902-2274 1373

62

limit 61 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or controlled clinical trial or multicenter study or observational study or randomized controlled trial or pragmatic clinical trial or comparative study or controlled clinical trial or evaluation studies or guideline or practice guideline or meta analysis or multicenter study or observational study or randomized controlled trial or pragmatic clinical trial or systematic reviews or validation studies) [Limit not valid in Embase,CCTR,CDSR; records were retained]

365

63 60 or 62 1697

64

limit 63 to (book or book series or editorial or erratum or letter or note or addresses or autobiography or bibliography or biography or comment or dictionary or directory or interactive tutorial or interview or lectures or legal cases or legislation or news or newspaper article or overall or patient education handout or periodical index or portraits or published erratum or video-audio media or webcasts) [Limit not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) In-Process,CCTR,CDSR; records were retained]

50

65 63 not 64 164766 from 12 keep 2275-2369 9567 65 or 66 1664

68limit 67 to ("all adult (19 plus years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)") [Limit not valid in Embase,CCTR,CDSR; records were retained]

1418

69 limit 68 to (adult <18 to 64 years> or aged <65+ years>) [Limit not valid in Ovid MEDLINE(R),Ovid MEDLINE(R) In- 1167

6

Process,CCTR,CDSR; records were retained]70 67 and (adult or adults or "middle age" or "middle aged").mp. 110171 69 or 70 120972 limit 71 to yr="1970 -Current" 120973 remove duplicates from 72 837

Table I: Characteristics of the included studies:Study ID Patients characteristic Co Intervention Cohort selection Lost to

follow upCante, 19981 End stage renal disease (ESRD) NA None reported or

unclear samplingNot reported

Dhingra, 20012 ESRD NA Our experience Not

7

(All patients) reported

Keuter, 20083 Patients with radiocephalic or brachiocephalic arteriovenous fistulas failure, on aspirin unless already on anticoagulation

NA Our experience (All patients)

Not reported

D’Ayala, 20084 ESRD Systemic heparin 57 patients a consecutive sample

2.609

Fassiadis, 20075 ESRD NA a consecutive sample

Not reported

Elwakeel, 20076 ESRD with no suitable superficial vein NA Our experience (All patients)

Not reported

Keeling, 2007 7 ESRD NA a consecutive sample

7.965

Nikeghbalian, 20068

ESRD NA Our experience (All patients)

Not reported

MAYA, 20059 ESRD NA Our experience (All patients)

Not reported

Rooijens, 2005 10 ESRD NA a consecutive sample

3.846

Madden, 2005 11 ESRD NA Our experience (All patients)

Not reported

Chen, 200512 ESRD Outflow Venovenostomy Our experience 0

8

(All patients)

Akoh, 200513 ESRD NA Our experience (All patients)

0.45

Brueck, 2004 14 ESRD NA a consecutive sample

Not reported

Di Iorio, 200415 ESRD NA Our experience (All patients)

Not reported

Rao, 2004 16 ESRD NA Our experience (All patients)

27

KAO, 200417 ESRD NA Our experience (All patients)

Not reported

Flarup, 200318 ESRD NA Our experience (All patients)

Not reported

Segal, 200319 ESRD NA Our experience (All patients)

Not reported

Gallieni, 2002 20 ESRD NA Our experience (All patients)

Not reported

Hingorani, 2001 21 ESRD NA Our experience (All patients)

Not reported

Berman, 200122 ESRD NA Our experience (All patients)

Not reported

vogel, 200023 ESRD NA a consecutive 0

9

sample

Miller, 1999 24 ESRD NA Our experience (All patients)

2.58621

khadra, 1997 25 ESRD NA Our experience (All patients)

Not reported

PALDER, 1985 26 ESRD NA Our experience (All patients)

Not reported

Rabbani, 2006 27 ESRD NA Our experience (All patients)

Not reported

SENKAYA, 200628


Not reported

Hood, 199429 ESRD Percutaneous balloon angioplasty Our experience (All patients)

Not reported

BRUNORI, 200030 ESRD NA Our experience (All patients)

Not reported

Choi, 200331 ESRD NA a consecutive sample

0

Dixon, 200232 ESRD NA Our experience (All patients)

Not reported

Matsuura, 199833 ESRD NA a consecutive sample

Not reported

Silva, 199834 ESRD Doppler pressures and duplex Our experience Not

10

ultrasound with mapping (All patients) reported

Staramos, 200035 ESRD NA a consecutive sample

1.75

Kokkosis, 2013 36 Cardiovascular comorbidity NA Our experience (All patients)

0

Goldfarb-Rumyantze, 201337

Renal transplantation NA None reported or unclear sampling

Not reported

Al-Benna, 201338 ESRD NA Our experience (All patients)

Not reported

Sahin, 2011 39 ESRD Duplex Doppler Our experience (All patients)

0

Chiulli, 201140 ESRD NA Our experience (All patients)

Not reported

Bonforte, 2010 41 ESRD NA Our experience (All patients)

Not reported

Ferring, 201042 ESRD NA Our experience (All patients)

0

Kybartiene, 201043 ESRD Antibiotics Our experience (All patients)

2

Stuard, 201044 ESRD Clopidogrel or aspirin with or without heparin

Our experience (All patients)

Not reported

Garcia Cortes, ESRD NA None reported or Not

11

200545 unclear sampling reported

Jimenez-Almonacid, 2004 46

ESRD NA a consecutive sample

Not reported

Hernandez-Jaras, 200447


Not reported

Rodriguez, 200148 ESRD NA Our experience (All patients)

Not reported

Branger, 201149 ESRD NA Our experience (All patients)

Not reported

Kennealey, 201150 ESRD NA Our experience (All patients)

Not reported

Diehm, 201051 ESRD NA Our experience (All patients)

Not reported

Wasse, 200852 ESRD NA Our experience (All patients)

Not reported

Ko, 200953 Patients without suitable superficial veins NA Our experience (All patients)

Not reported

Slayden, 200854 ESRD converting arteriovenous grafts to Secondary arteriovenous fistulas

a consecutive sample

Not reported

EKBAL, 200855 ESRD NA Our experience (All patients)

Not reported

12

Tsoulfas, 200856 ESRD NA Our experience (All patients)

Not reported

Long, 200857 ESRD with peri anastomotic stenosis Surgery or angioplasty Our experience (All patients)

0

Qasaimeh, 200858 ESRD NA Our experience (All patients)

0

Bronder, 200859 ESRD Fistula Elevation Procedure Consecutive Not reported

Torina, 200860 ESRD NA Our experience (All patients)

Not reported

Shahnawaz, 201361 ESRD NA Our experience (All patients)

Not reported

Morale, 201162 ESRD NA Our experience (All patients)

10

Lee, 201163 ESRD Preoperative ultra sound None reported or unclear sampling

Not reported

Moussavi, 200764 ESRD NA a consecutive sample

Not reported

Savader, 200065 ESRD NA Our experience (All patients)

Not reported

Hurlbert, 199866 ESRD NA a consecutive sample

0

13

McLaughlin, 199767

ESRD Antibiotics 1 g IV vancomycin Our experience (All patients)

Not reported

Ozlem, 199668 ESRD NA Our experience (All patients)

Not reported

Tedoriya, 199569 ESRD NA Our experience (All patients)

Not reported

Beigi, 200970 ESRD NA a consecutive sample

Not reported

Gormus, 200371 ESRD NA None reported or unclear sampling

Not reported

Polo, 200472 ESRD NA a consecutive sample

0

Ascher, 200173 ESRD Preoperative ultra sound Our experience (All patients)

Not reported

Astor, 200574 ESRD NA Our experience (All patients)

Not reported

Coburn, 199475 ESRD NA Our experience (All patients)

1.235

Haimov, 198076 ESRD NA Our experience (All patients)

Not reported

Hazinedaroglu, 200477

ESRD Preoperative venography, prophylactic dose of 1.5 g


Not reported

14

ampicillin + sulbactam IV

Kherlakian, 198678 ESRD NA Our experience (All patients)

Not reported

Kim, 199579 ESRD NA Our experience (All patients)

Not reported

Oliver, 200180 ESRD NA None reported or unclear sampling

3.77

Perera, 200481 ESRD NA a consecutive sample

13.39713

Polkinghorne, 200482

ESRD in Australia and New Zealand NA Our experience (All patients)

0

Ridao-Cano, 200283

ESRD Preoperative venography Our experience (All patients)

4.931

Sparks, 199784 ESRD NA Our experience (All patients)

Not reported

Tordoir, 198385 ESRD NA Our experience (All patients)

Not reported

Shemesh, 200886 Recurrent cephalic arch stenosis >50% within 3 months of successful balloon angioplasty

Endovascular intervention + preoperative ultra sound


0

Flu, 200887 ESRD NA a consecutive sample

0

15

Kakkos, 200888 ESRD NA a consecutive sample

0.5

Wu, 200889 ESRD with access dysfunction Balloon angioplasty for dialysis access dysfunction or thrombosis


Not reported

Kakkos, 200890 ESRD NA a consecutive sample

Not reported

Jean -Baptiste, 200891

ESRD Preoperative ultra sound Our experience (All patients)

0

Schild, 200792 ESRD HIV without sufficient veins for an autologous fistula

NA a consecutive sample

Not reported

Moossavi, 200793 ESRD Surgeon experience, interventional radiologists, intervention within 48 hours of thrombosis


Not reported

Woo, 200794 ESRD Preoperative ultra sound Our experience (All patients)

Not reported

Kayacioglu, 200795 ESRD, with diabetes NA None reported or unclear sampling

Not reported

Lee, 200796 ESRD Preoperative mapping, Surgeon experience


Not reported

Shemesh, 200797 ESRD Single dose of Cefamezine a consecutive sample

1.515

Basaran, 200798 ESRD Anti-platelets aspirin 300 mg/day None reported or Not

16

unclear sampling reported

Korten, 200799 ESRD Preoperative ultra sound a consecutive sample

Not reported

Yilmaz, 2007100 ESRD, 1-4 previous access attempts NA a consecutive sample

7.1

Mitchell, 2007101 ERSD HIV (+) vs. (-) NA Our experience (All patients)

Not reported

Inrig, 2006102 ESRD, Patients with Staphylococcus aureus Bacteremia

Surgical and percutaneous treatment of thrombosis, preoperative ultra sound


0

Karakayali, 2006103


Not reported

El Sayed, 2005104 ESRD Preoperative ultra sound Our experience (All patients)

14.1

Fitzgerald, 2005105 ESRD Preoperative ultra sound, preoperative venography


Not reported

Modarai, 2005106 ESRD, Radiocephalic, brachiocephalic and brachiobasilic fistulas not possible

NA Our experience (All patients)

Not reported

Kizilisik, 2004107 ESRD NA Our experience (All patients)

Not reported

Ko, 2004108 ESRD NA a consecutive sample

Not reported

17

Fitzgerald, 2004109 ESRD NA Our experience (All patients)

Not reported

Mazzoni, 2003110 ESRD Preoperative ultra sound Our experience (All patients)

0

Senkaya, 2003111 ESRD 300mg aspirin None reported or unclear sampling

0

Xue, 2003112 ESRD NA a consecutive sample

Not reported

Shenoy, 2003113 ESRD NA Our experience (All patients)

Not reported

Bruns, 2003114 ESRD NA Our experience (All patients)

8.2

Wiese, 2003115 ESRD, absence of sufficient native vessels to create an AV fistula

Color Doppler ultrasound Our experience (All patients)

6.7

Baldrati, 2003116 ESRD NA a consecutive sample

Not reported

Hossny, 2003117 ESRD NA Our experience (All patients)

2.857

Dalman, 2002118 ESRD NA a consecutive sample

Not reported

Sorom, 2002119 ESRD Preoperative ultra sound, 1 aspirin daily


Not reported

18

Ascher, 2001120 ESRD NA Our experience (All patients)

Not reported

Wolowczyk, 2000121


35

Taylor, 1996122 ESRD First generation cephalosporin or vancomycin given at dialysis


Not reported

Helling, 1992123 ESRD NA a consecutive sample

Not reported

Nannery, 1991124 ESRD, HIV, IV drug abusers NA Our experience (All patients)

0

Donnelly, 1988125 ESRD Heparin Our experience (All patients)

Not reported

Rizzuti, 1988126 ESRD Antibiotics Our experience (All patients)

Not reported

Elwakeel, 2013127 ESRD patients with no suitable vein to perform autogenous arteriovenous fistulas

Preoperative ultra sound Our experience (All patients)

Not reported

Fredette, 2013128 ESRD in Octogenarian (>80 years old) Vascular mapping Our experience (All patients)

Not reported

Scarritt, 2014129 ESRD not appropriate candidates for a primary fistula

NA a consecutive sample

Not reported

Hruby, 2013130 ESRD Duplex Doppler Ultrasound Our experience Not

19

(All patients) reported

Kanko, 2012131 ESRD NA a consecutive sample

Not reported

Gage, 2012132 ESRD NA Our experience (All patients)

Not reported

Basel, 2011133 ESRD Duplex scanning a consecutive sample

Not reported

Walker, 2012134 ESRD Duplex scanning Our experience (All patients)

Not reported

Huddam, 2012135 ESRD NA None reported or unclear sampling

Not reported

Woo, 2012136 ESRD NA Our experience (All patients)

Not reported

Lukowsky, 2012137 ESRD NA Our experience (All patients)

Not reported

Solid, 2012138 ESRD NA Our experience (All patients)

Not reported

Matsumoto, 2012139

ESRD Preoperative ultra sound Our experience (All patients)

Not reported

Desilva, 2012140 ESRD NA Our experience (All patients)

Not reported

Vahedian, 2012141 ESRD Preoperative ultra sound Our experience 0

20

(All patients)

Jackson, 2011142 ESRD with Angiotensin receptor blocker VS. No Angiotensin receptor blocker

NA None reported or unclear sampling

Not reported

Chan, 2011143 ESRD NA Our experience (All patients)

Not reported

Conte, 2011144 ESRD, Cardiovascular comorbidity Vascugel or placebo prior to surgery

None reported or unclear sampling

6.45

Powell, 2010145 ESRD Preoperative ultra sound, preoperative venography


Not reported

Karakayali, 2007146

ESRD Preoperative ultra sound, preoperative venography


Not reported

Hamida, 2005147 ESRD NA None reported or unclear sampling

Not reported

Cetinkaya, 2003148 ESRD NA None reported or unclear sampling

Not reported

Gorski, 2002149 HIV NA a consecutive sample

Not reported

Ravani, 2002150 ESRD Preoperative ultra sound a consecutive sample

Not reported

BACCHINI, 2001151

ESRD, impairment of native AVF NA None reported or unclear sampling

Not reported

Friedman, 2000152 ESRD NA None reported or 5.83

21

unclear sampling

Leapman, 1995153 ESRD NA None reported or unclear sampling

0

Cohen, 1994154 ESRD who underwent thrombolysis for thrombosed hemodialysis

Percutaneous transluminal balloon angioplasty


13

Viron, 1987155 ESRD NA None reported or unclear sampling

Not reported

Weale, 2008156 ESRD Preoperative ultra sound Our experience (All patients)

14.29

Gargiulo, 1999157 ESRD Antibiotics, preoperative ultra sound


17.65

Mortazavi, 2011158 ESRD NA Our experience (All patients)

0

Gibson, 2001159 ESRD NA a consecutive sample

Not reported

Taylor, 1993160 ESRD NA None reported or unclear sampling

Not reported

Morosetti, 2011161 ESRD Ceftazidime (1 g) was administered as a single-dose therapy


Not reported

Chen, 2010162 ESRD NA None reported or unclear sampling

Not reported

22

Gonzalez, 2010163 ESRD NA a consecutive sample

Not reported

Dember, 2008164 ESRD Preoperative ultra sound a consecutive sample

3.763

Louridas 165, 1984 ESRD NA Our experience (All patients)

Not reported

Foley, 2009166 ESRD NA a consecutive sample

Not reported

Salman, 2009167 ESRD Preoperative venography Our experience (All patients)

Not reported

Bradbury, 2009168 ESRD NA a consecutive sample

Not reported

Pisoni, 2009169 ESRD NA a consecutive sample

Not reported

Bhomi, 2008170 ESRD 5000 IU of intravenous heparin during surgery vs no heparin


Not reported

Grubbs, 2013171 ESRD NA Our experience (All patients)

Not reported

Jemcov, 2013172 ESRD Preoperative ultra sound a consecutive sample

Not reported

Alhassan, 2013173 ESRD in Nigerians NA a consecutive sample

2.87

23

Ilhan, 2013174 ESRD Preoperative ultra sound Our experience (All patients)

Not reported

Manson, 2012175 ESRD Opti-Flow Vascular Anastomosis Device


Not reported

Wongkonkitsin, 2014176

ESRD in Thai Preoperative ultra sound Our experience (All patients)

Not reported

Watorek, 2014177 ESRD in Octogenarian (>80 years old) NA Our experience (All patients)

Not reported

Wetzig, 1985178 ESRD Preoperative venography, bilateral upper extremity central venograms


0

Hart, 2014179 ESRD NA Our experience (All patients)

0

Persic, 2013180 ESRD Preoperative ultra sound Our experience (All patients)

2.5

Prischl, 1995181 ESRD Preoperative ultra sound a consecutive sample

Not reported

Kaufman, 1997182 ESRD Preoperative ultra sound a consecutive sample

1.7

Lok, 2005183 ESRD NA a consecutive sample

Not reported

Vaux, 2013184 ESRD NA Our experience (All patients)

0

24

Bender, 1995185 ESRD NA Our experience (All patients)

Not reported

Yasuhara, 1997186 ESRD NA Our experience (All patients)

Not reported

Wang, 1996187 ESRD Antibiotics Our experience (All patients)

Not reported

kalman, 1999188 ESRD NA a consecutive sample

Not reported

ELCHEROTH, 1994189


Not reported

Simoni, 1994190 ESRD NA Our experience (All patients)

Not reported

Rubens, 1993191 ESRD NA Our experience (All patients)

Not reported

BURT, 2001192 ESRD NA a consecutive sample

Not reported

Golledge, 1999193 ESRD NA our experience (All patients)

not reported

Lemson, 2000194 ESRD Antibiotics a consecutive sample

not reported

Curi, 1999195 ESRD HIV (+) vs. (-) NA our experience 1.92%

Munda, 1983196 ESRD NA our experience not

25

(all patients) reported

Silva, 1997197 ESRD Preoperative ultra sound our experience (all patients)

0

Hakaim, 1997198 ESRD NA our experience (all patients)

not reported

Bone, 1980199 ESRD 1 g of cephalothin a consecutive sample

not reported

Hibberd, 1991200 ESRD primary vascular access was not possible

All had pre-operative upper limb venography


not reported

Table II: Outcomes (rate, 95% confidence interval) per vascular access type:Group Primary

PatencySecondary Patency

Assisted Patency

Mortality Maturation Infection

Arteriovenous fistula 0.548 (0.522- 0.576) at 104 weeks*

0.627 (0.586- 0.670) at 104 weeks

0.787 (0.743- 0.834) at 65 weeks

0.153 (0.125- 0.187) at 104 weeks

0.827 (0.773- 0.885) at 26 weeks

0.021 (0.010 - 0.043) at 104 weeks

Arteriovenous graft 0.395 (0.353- 0.442) at 104 weeks

0.599 (0.548- 0.653) at 104 weeks

0.527 (0.422- 0.658) at 52 weeks

0.170 (0.135- 0.215) at 71.5 weeks

0.960 (0.858- 1.074) at 39 weeks

0.127 (0.097- 0.166) at 104 weeks

26

Catheter 0.499 (0.408-0.609) at 86 weeks

0.429 (0.267-0.687) at 39 weeks

0.763 (0.499-1.165) at 26 weeks

0.256 (0.203- 0.323) at 112 weeks

0.164 (0.078-0.344) at 59 weeks

HeRO 0.429 (0.361-0.510) at 104 weeks

0.704 (0.391-1.270) at 78 weeks

0.178 (0.128-0.248) at 122.8 weeks

0.038 (0.016-0.086) at 122.8 weeks

*The follow up is reported as median for all outcomes.

Table III: Outcomes (rate, 95% confidence interval) per subgroups for each vascular access type:

III.1: Arteriovenous fistula (AVF), unspecified location:Group Primary


Assisted Patency


Overall. 0.556 (0.512-0.605) at 91 weeks

0.652 (0.590-0.720) at 104 weeks

0.687 (0.580-0.812) at 52 weeks

0.152 (0.117-0.196) at 69 weeks

0.813 (0.676-0.978) at 19.5 weeks

0.023 (0.007-0.074) at 93 weeks

Age <50. 0 at 56 weeks 0 at 56 weeks

27

Age <65. 0.684 (0.642-0.729) at 130 weeks

0.800 (0.760-0.841) at 156 weeks

Age >40. 0.818 (0.700-0.956) at 52 weeks

Age >65. 0.686 (0.620-0.759) at 104 weeks

0.818 (0.745-0.898) at 130 weeks

0.249 (0.239-0.260) at 52 weeks

Age >70. 0.441 (0.332-0.586) at 156 weeks

0.441 (0.332-0.586) at 156 weeks

0.333 (0.146-0.761) at 52 weeks

0.133 (0.027-0.659) at 130 weeks

Age >75. 0.588 (0.374- 0.926) at 86 weeks

0.176 (0.052-0.597) at 130 weeks

Age >80. 0.294 (0.166-0.522) at 216 weeks

0.294 (0.166-0.522) at 156 weeks

Age 50-60.* 0.341 (0.215-0.542) at 86 weeks

0.366 (0.236-0.567) at 130 weeks

0.118 (0.041-0.339) at 156 weeks

Currently dialyzing through a catheter.

0.554 (0.446-0.688) at 104 weeks

0.246 (0.236-0.256) at 52 weeks

Diabetes Mellitus. 0.524 (0.422-0.651) at 44.5 weeks

0.598 (0.262-1.365) at 454 weeks

0.235 (0.198-0.278) at 52 weeks

Women. 0.062 (0.005-0.864) at 104 weeks

28

History of previous access failure.

0.578 (0.503-0.663) at 84.5 weeks

0.901 (0.850-0.956) at 104 weeks

Inflow artery minimum diameter 2-2.5 mm.

0.873 (0.810-0.940) at 26 weeks

0.958 (0.917-1.000) at 4 weeks

Men. 0 at 56 weeks 0 at 56 weeks

No Diabetes Mellitus. 0.366 (0.280-0.480) at 65 weeks

0.884 (0.804-0.972) at 936 weeks

0.207 (0.182-0.236) at 52 weeks

Non dominant side. 0.486 (0.324-0.729) at 26 weeks

0.367 (0.310-0.434) at 572 weeks

Pre-dialysis: anticipated start 1 year.

0.769 (0.696-0.850) at 104 weeks

Upper extremity minimum outflow vein diameter >3 mm.

0.900 (0.671-1.207) at 6 weeks

Upper extremity minimum outflow vein diameter 2.5-3 mm.

0.491 (0.426-0.565) at 104 weeks

Upper extremity minimum outflow vein diameter 2-2.5 mm.

0.873 (0.810-0.940) at 26 weeks

0.958 (0.917-1.000) at 4 weeks

* Results are mutually exclusive to this subgroup.

III.2: Upper arm AVF:Group Primary Secondary Assisted Mortality Maturation Infection

29

Patency Patency PatencyOverall. 0.535 (0.429-

0.668) at 104 weeks

0.671 (0.545-0.826) at 104 weeks

0.698 (0.589-0.792) at 104 weeks

0.047 (0.001-1.646) at 104 weeks

0.972 (0.937-1.009) at 82 weeks

0 at 82 weeks

Age >70. 0.552 (0.384-0.792) at 104 weeks

III.3: Brachial- Basilic fistula:Group Primary


Assisted Patency


Overall. 0.582 (0.511-0.664) at 104 weeks

0.722 (0.645-0.809) at 91 weeks

0.857 (0.736-0.998) at 65 weeks

0.104 (0.054-0.201) at 104 weeks

0.780 (0.685-0.888) at 34.15 weeks

0.019 (0.004-0.092) at 115 weeks

Age <65. 0.357 (0.158-0.805) at 104 weeks

Age >65. 0.364 (0.144-0.915) at 52 weeks

Black. 0.600 (0.456-0.790) at 115 weeks

Diabetes Mellitus. 0.947 (0.862-1.041) at 52 weeks

0.84 (0.720-0.985) at 52 weeks

Women. 0.658 (0.422-1.025) at 109.5 weeks

30

Men. 0.933 (0.827-1.053) at 104 weeks

Non dominant side. 0.900 (0.671-1.207 ) at 43 weeks

0 at 43 weeks 0 at 43 weeks

Upper extremity minimum outflow vein diameter >3 mm.

0.900 (0.671-1.207) at 43 weeks



0.480(0.372-0.620) at 260 weeks

0.648 (0.574-0.732) at 260 weeks

0.042 (0.016-0.111) at 4 weeks

0.025 (0.007-0.093) at 121 weeks

III.4: Brachial-brachial fistula:Group Primary


Assisted Patency


Overall. 0.586 (0.457- 0.751) at 92 weeks

0.455 (0.213-0.972) at 52 weeks

0.143 (0.03-0.363) at 125 weeks

0.213 (0.026-1.719) at 78 weeks

III.5: Brachial-Cephalic fistula:Group Primary


Assisted Patency


Overall. 0.526 (0.458-0.604) at 130 weeks

0.573 (0.435-0.755) at 104.5 weeks

0.966 (0.950-0.983) at 260 weeks

0.325 (0.175-0.603) at 93.4 weeks

0.863 (0.588- 1.268) at 6 weeks

0.001 (0.000-0.685) at 130 weeks

Age <65. 0.475 (0.245-0.920) at 156 weeks

0.339 (0.262-0.437) at 105 weeks

31

Age >65. 0.452 (0.357-0.572) at 156 weeks

Age >80. 0.592 (0.329-1.065) at 156 weeks

0.429 (0.303-0.607) at 104 weeks

Age 60-70. 0.820 (0.753-0.894) at 208 weeks

Age 65-80. 0.543 (0.263-1.118) at 156 weeks

0.388 (0.307-0.491) at 105 weeks

BMI < 18. 0.686 (0.536-0.878) at 208 weeks

BMI > 25. 0.893 (0.845-0.943) at 208 weeks

BMI 18-25. 0.737 (0.682-0.796) at 208 weeks

Women. 0.772 (0.711-0.838) at 208 weeks


0.802 (0.727-0.885) at 537 weeks

Men. 0.804 (0.756-0.854) at 208 weeks

32


0.394 (0.290-0.536) at 260 weeks

0.465 (0.357-0.606) at 260 weeks


III.6: Forearm AVF:Group Primary


Assisted Patency


Overall. 0.460 (0.293-0.721) at 156 weeks

0.905 (0.869-0.941) at 260 weeks

0.431 (0.293-0.578) at 260 weeks

0 at 104 weeks


0.823 (0.736-0.919) at 260 weeks

0.431 (0.293-0.578) at 260 weeks


0.922 (0.883-0.962) at 260 weeks

III.7: Radiocephalic fistula:Group Primary


Assisted Patency


Overall. 0.554 (0.505-0.608) at 104 weeks

0.536 (0.423-0.679) at 104 weeks

0.858 (0.754-0.976) at 52 weeks

0.173 (0.114-0.263) at 104 weeks

0.781 (0.647-0.943)4 at 45.5 weeks

0.021 (0.007-0.064) at 156 weeks

Age <50. 0.511 (0.375-0.696) at 156 weeks

Age <60. 0.538 (0.363-0.799) at 104 weeks

0.654 (0.478-0.893) at 104 weeks

0.269 (0.132-0.547) at 104 weeks

0.923 (0.803-1.062) at 104 weeks

33

Age <65. 0.319 (0.239-0.426) at 130 weeks

0.280 (0.216-0.362) at 104 weeks

Age <70. 0.560 (0.478-0.655) at 260 weeks

Age >60. 0.593 (0.419-0.838) at 104 weeks

0.630 (0.456-0.868) at 104 weeks

0.185 (0.075-0.455) at 104 weeks

0.741 (0.576-0.953) at 104 weeks

Age >65. 0.413 (0.319-0.534) at 156 weeks

0.047 (0.009-0.245) at 104 weeks

Age >70. 0.337 (0.245-0.462) at 208 weeks

Age >80. 0.383 (0.259-0.566) at 104 weeks

0.404 (0.278-0.588) at 104 weeks

Age 50-59. 0.364 (0.196-0.675) at 156 weeks

Age 60-69. 0.364 (0.222-0.596) at 156 weeks

Age 65-79. 0.359 (0.288-0.448) at 104 weeks

0.373 (0.301-0.462) at 104 weeks

Current Smoking 0.591 (0.400-0.873) at 78 weeks

Currently dialyzing 0.447 (0.374-

34

through a catheter. 0.535) at 260 weeks


0.500 (0.337-0.741) at 104 weeks

Women. 0.200 (0.145-0.277) at 156 weeks

0.441 (0.292-0.667) at 104 weeks

0.857 (0.761-0.966) at 8 weeks


0.680 (0.606-0.764) at 520 weeks

Inflow artery minimum diameter 2-2.5 mm.

0.745 (0.620-0.894) at 52 weeks

0.924 (0.854-1.000) at 8 weeks

Inflow artery minimum diameter >2.5 mm.

0.524 (0.383-0.716) at 52 weeks

Inflow artery minimum diameter 1.5-2 mm.

0.480 (0.352-0.655) at 52 weeks

0.857 (0.761-0.966) at 8 weeks

Left side. 0.474 (0.380-0.591) at 52 weeks

Men. 0.550 (0.437-0.693) at 156 weeks

0.730 (0.629-0.847) at 105 weeks

0.924 (0.854-1.000) at 8 weeks

Never Smoke. 0.825 (0.729-0.935) at 78 weeks

35


0.701 (0.600-0.819) at 104 weeks


0.351 (0.290-0.425)

0.782 (0.681-0.897) at 42 weeks

Pre-dialysis: Anticipated start 6 months to 1 year.

0.532 (0.398-0.710) at 260 weeks

Pre-dialysis: Anticipated start in 1 year.

0.532 (0.398-0.710) at 260 weeks

Pre-dialysis: Anticipated start less than 6 months.

0.532 (0.398-0.710) at 260 weeks

Upper extremity minimum outflow vein diameter <1 mm.

0.650 (0.451-0.936) at 78 weeks

Upper extremity minimum outflow vein diameter 2-2.5 mm.

0.902 (0.84-0.967) at 8 weeks

III.8: Forearm basilic fistula:Group Primary


Assisted Patency


Overall. 0.377 (0.184-0.774) at 104 weeks

0.627 (0.436-0.902) at 80.6 weeks

0.288 (0.221-0.363) at 208 weeks

0.051 (0.019-0.134) at 104 weeks

0 at 104 weeks

36

III.9: Lower extremity fistula:Group Primary


Assisted Patency


Overall. 0.460 (0.189-1.122) at 52 weeks

0.727 (0.469-1.129) at 39 weeks

0 (0.000-6.500) at 40.6 weeks


0 at 52 weeks


0.267 (0.100-0.709) at 29.2 weeks

III.10: Arteriovenous graft (AVG), unspecified location:Group Primary


Assisted Patency


Overall. 0.373 (0.324-0.430) at 104 weeks

0.641 (0.590-0.696) at 104 weeks

0.459 (0.349-0.602) at 52 weeks

0.175 (0.129-0.237) at 52 weeks

0.123 (0.079-0.190) at 104 weeks

Age <50. 0.118 (0.024-0.588) at 43 weeks

0.200 (0.051-0.782) at 43 weeks

Age <65. 0.401 (0.325-0.496) at 130 weeks

0.748 (0.676-0.828) at 156 weeks

Age >40. 0.536 (0.366-0.784) at 52 weeks

37

Age >65. 0.372 (0.292-0.474) at 130 weeks

0.718 (0.635-0.813) at 156 weeks

0.281 (0.275-0.288) at 52 weeks


Women. 0.500 (0.342-0.731) at 104 weeks

0.750 (0.600-0.938) at 104 weeks

0.500 (0.056-4.430) at 43 weeks

Men. 0.467 (0.251-0.867) at 104 weeks

0.467 (0.251-0.867) at 104 weeks

0.118 (0.024-0.588) at 43 weeks

0.118 (0.024-0.588) at 43 weeks




0.300 (0.225-0.400) at 104 weeks

III.11: Upper arm graft:Group Primary


Assisted Patency


Overall. 0.441 (0.354-0.550) at 88.5 weeks

0.391 (0.229-0.666) at 104 weeks

0.492 (0.213-1.133) at 52 weeks

0.121 (0.055-0.262) at 78 weeks

0.886 (0.733-0.968) at 13 weeks

0.116 (0.057-0.234) at 112.5 weeks

38

Age <71. 0.586 (0.475-0.722) at 156 weeks

0.886 (0.807-0.973) at 156 weeks

0.843 (0.754-0.942) at 156 weeks

0.100 (0.046-0.218) at 156 weeks

0.129 (0.066-0.251) at 156 weeks

Age 70-80. 0.641 (0.526-0.780) at 104 weeks


0.429 (0.246-0.745) at 13 weeks

Never Smoke. 0.327 (0.218-0.492) at 104 weeks


0.886 (0.807-0.973) at 156 weeks

0.843 (0.754-0.942) at 156 weeks

0.100 (0.046-0.218) at 156 weeks

0.129 (0.066-0.251) at 156 weeks

III.12: Forearm graft:Group Primary


Assisted Patency


Overall. 0.332 (0.247-0.447) at 104 weeks

0.463 (0.203-1.053) at 86 weeks

0.667 (0.543-0.820) at 86 weeks

0.222 (0.135-0.363) at 58.5 weeks

1.000 (0.970-1.031) at 65 weeks

0.114 (0.075-0.174) at 145 weeks


Men. 0.650 (0.451-0.936) at 104 weeks

0.100 (0.020-0.507) at 117 weeks

39

III.13: Axillary-Axillary graft:Group Primary


Assisted Patency


Overall. 0.513 (0.283-0.931) at 104 weeks

0.611 (0.333-1.118) at 91 weeks

0.142 (0.076-0.266) at 130 weeks

0.161 (0.089-0.290) at 130 weeks

Age >50. 0.519 (0.347-0.775) at 78 weeks

0.815 (0.662-1.002) at 78 weeks

0.185 (0.075-0.455) at 208 weeks

0.111 (0.032-0.391) at 208 weeks

III.14: Lower extremity graft:Group Primary


Assisted Patency


Overall. 0.583 (0.441-0.772) at 104 weeks

0.182 (0.038-0.866) at 104 weeks

0.333 (0.191-0.502) at 572 weeks

0.202 (0.158-0.258) at 52 weeks

Currently dialyzing through a catheter.

0.467 (0.333-0.654) at 104 weeks

0.178 (0.089-0.356) at 572 weeks


0.467 (0.333-0.654) at 104 weeks

0.178 (0.089-0.356) at 572 weeks


0.353 (0.169-0.735) at 52 weeks

III.15: Tunneled cuffed catheter, unspecified location:Group Primary


Assisted Patency


40

Overall. 0.452 (0.296-0.692) at 156 weeks

0.429 (0.245-0.628) at 39 weeks

0.357 (0.243-0.525) at 52 weeks

0.167 (0.083-0.285) at 29 weeks

Age >67. 0.415 (0.410-0.420) at 52 weeks

Age >80. 0.600 (0.446-0.807) at 156 weeks

0.600 (0.446-0.807) at 156 weeks

Age 50-60. 0.429 (0.246-0.745) at 156 weeks

0.429 (0.246-0.745) at 156 weeks


0.167 (0.083-0.285) at 29 weeks

III.16: Tunneled cuffed IJ/subclavian PermCath:Group Primary


Assisted Patency


Overall. 0.511 (0.411-0.637) at 82 weeks

0.763 (0.499-1.165) at 26 weeks

0.211 (0.130-0.343) at 116.5 weeks

0.163 (0.075-0.356) at 83.5 weeks

Age >70. 0.073 (0.038-0.140) at 78 weeks

0.102 (0.060-0.174) at 78 weeks

Age >75. 0.467(0.251-0.867) at 86 weeks

0.600 (0.373-0.966) at 130 weeks

41

III.17: Hybrid graft and catheter (HeRO):Group Primary


Assisted Patency


Overall. 0.429 (0.361-0.510) at 104 weeks

0.704 (0.391-1.270) at 78 weeks

0.178 (0.128-0.248) at 122.8 weeks

0.038 (0.016-0.086) at 122.8 weeks


0.091 (0.018-0.464) at 52 weeks

0.227 (0.094-0.547) at 52 weeks

HTN 0.091 (0.002-0.413) at 52 weeks

0.455 (0.167-0.766) at 52 weeks

42

Table IV: Average days to maturation:Study ID Sample

sizeAverage number of days

Mean (95%CI)

Weighted SD

Cohort

Kybartiene, 2010Garcia Cortes, 2005

288 22.62 (21.26-23.99) 11.81 AVF, unspecified location. Overall.

Garcia Cortes, 2005

17 69.70 (51.64-87.76) 38.00 AVF, unspecified location. Age >75.

Rao, 2004Yilmaz, 2007Fitzgerald, 2004

119 92.55 (85.23- 99.88) 40.80 Brachial- basilic fistula.

Hruby, 2013Vahedian, 2012Alhassan, 2013

181 40.30 (38.72-41.88) 10.85 Radiocephalic fistula. Overall

Alhassan, 2013 97 30.80(28.57-33.03) 11.20 Radiocephalic fistula. Left hand.

43

Table V: Summary results of meta-analysis of included comparative studies per access types:

5.1: AVF, unspecified location:Study ID Cohort 1 Cohort 2 Results

Persic, 2013 Age ≥65. DM Age ≥65. No DM Primary patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.5 (0.26-0.96)Secondary patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.51 (0.21-1.22)

Segal, 2003 BMI ≥30 BMI <30 Primary patency in Cohort 1 > Cohort 2. Not statistically significant, RR 1.09 (0.56-2.13)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.73 (0.34-1.54)

Ferring, 2010 No Cardiac disease Cardiac disease Primary patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.033 (0.597-1.788)Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.037 (0.555-1.936)

Ferring, 2010 non-Caucasian Caucasian Primary patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.951 (0.579-1.564)Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.364 (0.782-2.380)

44

Ferring, 2010 No DM DM Primary patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.504 (0.965-2.344)Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, HR 1.657 (0.989-2.777)

Ferring, 2010. Segal, 2003

Women Men Primary patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.607 (0.421-0.876)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, HR 0.590 (0.254-1.369)

Segal, 2003 Coronary artery disease (CAD) No CAD Primary patency in Cohort 1 > Cohort 2. Statistically significant, RR 2.5 (1.08-5.56)Assisted patency in Cohort 1 > Cohort 2. Not statistically significant, RR 1.49 (0.58-3.85)

Segal, 2003 DM No DM Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.7 (0.37-1.33)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.93 (0.41-2.08)

Segal, 2003 Previous access No Previous access Primary patency in Cohort 1 < Cohort 2. Statistically significant, RR 0.49 (0.26-0.92)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.47 (0.22-1.02)

45

Segal, 2003 Smoking No Smoking Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.81 (0.38-1.67)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.53 (0.21-1.32)

Segal, 2003 Black Non black Primary patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.56 (0.17-1.85)Assisted patency in Cohort 1 < Cohort 2. Not statistically significant, RR 0.45 (0.12-1.75)

Ferring, 2010 Not yet on hemodialysis On hemodialysis Primary patency in Cohort 1 > Cohort 2. Statistically significant, HR 2.196 (1.323-3.644)Assisted patency in Cohort 1 > Cohort 2. Statistically significant, HR 2.601 (1.473-4.594)

V.2: AVF, unspecified location VS. Tunneled cuffed catheters, unspecified location:Study ID Cohort 1 Cohort 2 ResultsIlhan, 2013. Lukowsky, 2012. Desilva, 2012

No subgroup reported. No subgroup reported. Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.839 (0.421-1.675)

Desilva, 2012 African American African American Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.63 (0.56-0.72)

Desilva, 2012 Age >90 Age >90 Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.69 (0.52-0.91)

46

Desilva, 2012 Age 70 - 80 Age 70 - 80 Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.56 (0.52-0.60)


Desilva, 2012 Asian Asian Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.50 (0.37-0.67)

Desilva, 2012 Comorbidity index 1 (0-8) Comorbidity index 1 (0-8) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.52 (0.49-0.56)

Desilva, 2012 Comorbidity index 2 (=9) Comorbidity index 2 (=9) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.61 (0.55-0.68)

Desilva, 2012 Comorbidity index 3 (>9) Comorbidity index 3 (>9) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.57 (0.52-0.63)

Desilva, 2012 DM DM Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.58 (0.54-0.62)

Desilva, 2012 Women Women Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.59 (0.54-0.64)

Desilva, 2012 Men Men Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.54 (0.51-0.57)

Desilva, 2012 Native American Native American Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.73 (0.40-1.32)

47

Desilva, 2012 No DM No DM Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.53 (0.50-0.57)

Desilva, 2012 White White Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.54 (0.52-0.58)

V.3: Forearm AVF VS. Upper-arm AVF:Study ID Cohort 1 Cohort 2 ResultsFerring, 2010 Forearm AVF Upper-arm AVF Primary patency in Cohort 1 < Cohort

2. Statistically significant, HR 0.448 (0.277-0.724)Assisted patency in Cohort 1 < Cohort 2. Statistically significant, HR 0.491 (0.284-0.849)

V.4: Tunneled cuffed catheters, unspecified location VS. AVF, unspecified location:Study ID Cohort 1 Cohort 2 ResultsWoo, 2012. Grubbs, 2013

Tunneled cuffed catheters, unspecified Autogenous upper extremity AVF, unspecified

Mortality in Cohort 1 > Cohort 2. Not statistically significant, HR 3.148 (0.774-12.808)

Foley, 2009 African American African American Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.19 (2.03-2.37)

Foley, 2009 Age >65 Age >65 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.14 (2.06-2.23)

48

Foley, 2009 Age ≤65 Age ≤65 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.31 (2.16-2.47)

Foley, 2009 Comorbid index ≥2 Comorbid index ≥2 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.03 (1.94–2.12)

Foley, 2009 Comorbid index 0 or 1 Comorbid index 0 or 1 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.37 (2.24–2.50)

Astor, 2005 Women Women Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.96 (0.50 to 1.87)

Foley, 2009 Hispanic Hispanic Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.23 (1.98-2.52)

Astor, 2005 Men Men Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.98 (1.16 to 3.38)

Foley, 2009 White White Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 2.18 (2.10-2.27)

V.5: AVG, unspecified location VS. AVF, unspecified location:Study ID Cohort 1 Cohort 2 ResultsWoo, 2012. Grubbs, 2013. Pisoni, 2009

No subgroup reported. No subgroup reported. Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.278 (1.139-1.435)

Foley, 2009 African American African American Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.33 (1.20-1.49)

49

Foley, 2009 Age > 65 Age >65 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.36 (1.28-1.45)

Foley, 2009 Age ≤65 Age ≤65 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.47 (1.32-1.63)

Foley, 2009 Comorbid index ≥2 Comorbid index ≥2 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.32(1.23–1.42)

Foley, 2009 Comorbid index 0 or 1 Comorbid index 0 or 1 Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.38(1.26–1.51)

Astor, 2005 Women Women Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.94 (0.51-1.72)

Foley, 2009 Hispanic Hispanic Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.38 (1.13-1.67)

Astor, 2005 Men Men Mortality in Cohort 1 > Cohort 2. Not statistically significant, HR 1.29 (0.75-2.22)

Foley, 2009 White White Mortality in Cohort 1 > Cohort 2. Statistically significant, HR 1.44 (1.35-1.54)

V.6: AVG, unspecified location VS. Tunneled cuffed catheters, unspecified location:Study ID Cohort 1 Cohort 2 Results

50

Goldfarb-Rumyantze, 2013Lukowsky, 2012Desilva, 2012

No subgroup reported. No subgroup reported. Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.922 (0.578-1.468)

Desilva, 2012 African American African American Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.77 (0.67-0.89)

Desilva, 2012 Age >90 Age >90 Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.83 (0.57-1.23)



Desilva, 2012 Asian Asian Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.67 (0.47-0.95)

Desilva, 2012 Comorbidity index 1 (0-8) Comorbidity index 1 (0-8) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.65 (0.58-0.73)

Desilva, 2012 Comorbidity index 2 (=9) Comorbidity index 2 (=9) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.78 (0.67-0.90)

Desilva, 2012 Comorbidity index 3 (>9) Comorbidity index 3 (>9) Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.85 (0.74-0.96)

Desilva, 2012 DM DM Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.78 (0.71-0.86)

51

Desilva, 2012 Women Women Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.68 (0.61-0.75)

Desilva, 2012 Men Men Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.82 (0.74-0.91)

Desilva, 2012 Native American Native American Mortality in Cohort 1 < Cohort 2. Not statistically significant, HR 0.86 (0.27-2.73)

Desilva, 2012 No DM No DM Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.70 (0.62-0.78)

Desilva, 2012 White White Mortality in Cohort 1 < Cohort 2. Statistically significant, HR 0.73 (0.67-0.80)

52

References:

1. Cante P, Bottet P, Ryckelynck JP, Roch BL, Levaltier B, Lobbedez T, et al. [Distal vascular access for chronic hemodialysis in

patients over 65 years of age. Surgical results]. Progres en Urologie. 1998;8(1):83-8.

2. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S.

hemodialysis patients. Kidney Int. 2001;60(4):1443-51.

3. Keuter XHA, Smet AAEAD, Kessels AGH, Sande FMvd, Welten RJTJ, Tordoir JHM. A randomized multicenter study of the

outcome of brachial-basilic arteriovenous fistula and prosthetic brachial-antecubital forearm loop as vascular access for hemodialysis.

Journal of Vascular Surgery. 2008;47(2):395-401.

4. Ayala MD, Smith RM, Martone C, Briggs W, Deitch JS, Wise L. The effect of systemic anticoagulation in patients undergoing

angioaccess surgery. Annals of Vascular Surgery. 2008;22(1):11-5.

5. Fassiadis N, Morsy M, Siva M, Marsh JE, Makanjuola AD, Chemla ES. Does the surgeon's experience impact on

radiocephalic fistula patency rates? Seminars in Dialysis. 2007;20(5):455-7.

6. Elwakeel HA, Saad EM, Elkiran YM, Awad I. Unusual vascular access for hemodialysis: transposed venae comitante of the

brachial artery. Annals of Vascular Surgery. 2007;21(5):560-3.

7. Keeling AN, Dwyer HO, Lyon S, Kelly PO, McGrath FP, Conlon PJ, et al. Do AshSplit haemodialysis catheters provide better

flow rates in the long term? Renal Failure. 2007;29(6):721-9.

53

8. Nikeghbalian S, Bananzadeh A, Yarmohammadi H. Difficult vascular access in patients with end-stage renal failure.

Transplantation Proceedings. 2006;38(5):1265-6.

9. Maya ID, Allon M. Outcomes of tunneled femoral hemodialysis catheters: comparison with internal jugular vein catheters.

Kidney International. 2005;68(6):2886-9.

10. Rooijens PPGM, Burgmans JPJ, Yo TI, Hop WCJ, Smet AAEAd, Dorpel MAvd, et al. Autogenous radial-cephalic or

prosthetic brachial-antecubital forearm loop AVF in patients with compromised vessels? A randomized, multicenter study of the

patency of primary hemodialysis access. Journal of Vascular Surgery. 2005;42(3):481-6; discussions 7.

11. Madden RL, Lipkowitz GS, Browne BJ, Kurbanov A. A comparison of cryopreserved vein allografts and prosthetic grafts for

hemodialysis access. Annals of Vascular Surgery. 2005;19(5):686-91.

12. Chen JC, Kamal DM, Jastrzebski J, Taylor DC. Venovenostomy for outflow venous obstruction in patients with upper

extremity autogenous hemodialysis arteriovenous access. Annals of Vascular Surgery. 2005;19(5):629-35.

13. Akoh JA, Sinha S, Dutta S, Opaluwa AS, Lawson H, Shaw JF, et al. A 5-year audit of haemodialysis access. Int J Clin Pract.

2005;59(7):847-51.

14. Brueck M, Waeger S, Braig G, Kramer W. [Subcutaneously tunnelled cuffed venous hemodialysis catheters in chronic renal

failure]. Deutsche Medizinische Wochenschrift. 2004;129(47):2529-34.

15. Iorio BRD, Bellizzi V, Cillo N, Cirillo M, Avella F, Andreucci VE, et al. Vascular access for hemodialysis: the impact on

morbidity and mortality. Journal of Nephrology. 2004;17(1):19-25.

54

16. Rao RK, Azin GD, Hood DB, Rowe VL, Kohl RD, Katz SG, et al. Basilic vein transposition fistula: a good option for

maintaining hemodialysis access site options? Journal of Vascular Surgery. 2004;39(5):1043-7.

17. Kao CL, Chang JP. The reverse upper arm curved graft with ringed PTFE graft as an alternative vascular access procedure for

hemodialysis. Journal of Cardiovascular Surgery. 2004;45(1):55-7.

18. Flarup S, Hadimeri H. Arteriovenous PTFE dialysis access in the lower extremity: a new approach. Annals of Vascular

Surgery. 2003;17(5):581-4.

19. Segal JH, Kayler LK, Henke P, Merion RM, Leavey S, Campbell DA, et al. Vascular access outcomes using the transposed

basilic vein arteriovenous fistula. American Journal of Kidney Diseases. 2003;42(1):151-7.

20. Gallieni M, Conz PA, Rizzioli E, Butti A, Brancaccio D. Placement, performance and complications of the Ash Split Cath

hemodialysis catheter. International Journal of Artificial Organs. 2002;25(12):1137-43.

21. Hingorani A, Ascher E, Kallakuri S, Greenberg S, Khanimov Y. Impact of reintervention for failing upper-extremity

arteriovenous autogenous access for hemodialysis. Journal of Vascular Surgery. 2001;34(6):1004-9.

22. Berman SS, Gentile AT. Impact of secondary procedures in autogenous arteriovenous fistula maturation and maintenance.

Journal of Vascular Surgery. 2001;34(5):866-71.

23. Vogel KM, Martino MA, Brien SPO, Kerstein MD. Complications of lower extremity arteriovenous grafts in patients with

end-stage renal disease. Southern Medical Journal. 2000;93(6):593-5.

55

24. Miller PE, Tolwani A, Luscy CP, Deierhoi MH, Bailey R, Redden DT, et al. Predictors of adequacy of arteriovenous fistulas in

hemodialysis patients. Kidney International. 1999;56(1):275-80.

25. Khadra MH, Dwyer AJ, Thompson JF. Advantages of polytetrafluoroethylene arteriovenous loops in the thigh for

hemodialysis access. American Journal of Surgery. 1997;173(4):280-3.

26. Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL. Vascular access for hemodialysis. Patency

rates and results of revision. Annals of Surgery. 1985;202(2):235-9.

27. Rabbani A, Moini M, Shojaeefard A. Comparison between native arteriovenous fistula and graft in patients referred for

hemodialysis access placement. Acta Medica Iranica. 2006;44 (6):395-9.

28. Senkaya I, Aytac IK, Percin B, Bicer M. Basilic vein transposition a good choice for vascular access for A-V fistulas.

Chirurgia. 2006;19 (2):145-8.

29. Hood DB, Yellin AE, Richman MF, Weaver FA, Katz MD. Hemodialysis graft salvage with endoluminal stents. American

Surgeon. 1994;60 (10):733-7.

30. Brunori G, Verzelletti F, Zubani R, Movilli E, Gaggiotti M, Cancarini G, et al. Which vascular access for chronic hemodialysis

in uremic elderly patients? J Vasc Access. 2000;1(4):134-8.

31. Choi HM, Lal BK, Cerveira JJ, Padberg FT, Jr., Silva MB, Jr., Hobson RW, 2nd, et al. Durability and cumulative functional

patency of transposed and nontransposed arteriovenous fistulas. J Vasc Surg. 2003;38(6):1206-12.

56

32. Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, et al. Effect of dipyridamole plus aspirin on

hemodialysis graft patency. N Engl J Med. 2009;360(21):2191-201.

33. Matsuura JH, Rosenthal D, Clark M, Shuler FW, Kirby L, Shotwell M, et al. Transposed basilic vein versus

polytetrafluorethylene for brachial-axillary arteriovenous fistulas. Am J Surg. 1998;176(2):219-21.

34. Silva MB, Jr., Hobson RW, 2nd, Pappas PJ, Jamil Z, Araki CT, Goldberg MC, et al. A strategy for increasing use of

autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation. J Vasc Surg. 1998;27(2):302-7;

discussion 7-8.

35. Staramos DN, Lazarides MK, Tzilalis VD, Ekonomou CS, Simopoulos CE, Dayantas JN. Patency of autologous and prosthetic

arteriovenous fistulas in elderly patients. Eur J Surg. 2000;166(10):777-81.

36. Kokkosis AA, Abramowitz SD, Schwitzer J, Schanzer H, Teodorescu VJ. Experience of HeRO dialysis graft placement in a

challenging population. Vascular & Endovascular Surgery. 2013;47(4):278-80.

37. Goldfarb-Rumyantzev AS, Yoon JH, Patibandla BK, Narra A, Sandhu GS, Desilva R. The role of initial hemodialysis vascular

access in the outcome of subsequent kidney transplantation. Clinical Transplantation. 2013;27(2):210-6.

38. Al-Benna S, Deardon D, Hamilton D, El-Enin H. Long-term outcome of upper limb autogenous arteriovenous fistulas for

hemodialysis access. Saudi Journal of Kidney Diseases & Transplantation. 2013;24(1):109-14.

39. Sahin L, Gul R, Mizrak A, Deniz H, Sahin M, Koruk S, et al. Ultrasound-guided infraclavicular brachial plexus block

enhances postoperative blood flow in arteriovenous fistulas. Journal of Vascular Surgery. 2011;54(3):749-53.

57

40. Chiulli LC, Vasilas P, Dardik A. Superior patency of upper arm arteriovenous fistulae in high risk patients. Journal of Surgical

Research. 2011;170(1):157-64.

41. Bonforte G, Rossi E, Auricchio S, Pogliani D, Mangano S, Mandolfo S, et al. The middle-arm fistula as a valuable surgical

approach in patients with end-stage renal disease. Journal of Vascular Surgery. 2010;52(6):1551-6.

42. Ferring M, Claridge M, Smith SA, Wilmink T. Routine preoperative vascular ultrasound improves patency and use of

arteriovenous fistulas for hemodialysis: a randomized trial. Clinical Journal of The American Society of Nephrology: CJASN.

2010;5(12):2236-44.

43. Kybartiene S, Skarupskiene I, Ziginskiene E, Kuzminskis V. Vascular access for hemodialysis: creation, functioning, and

complications (data of the Hospital of Kaunas University of Medicine). Medicina (Kaunas, Lithuania). 2010;46(8):550-5.

44. Stuard S, Belcaro G, Dugall M, Cesarone MR, Hosoi M, Errichi BM, et al. Patency of arteriovenous fistula for dialysis

improbe with topical spraygel heparin. Panminerva Medica. 2010;52(2 Suppl 1):33-6.

45. Garcia Cortes MJ, Viedma G, Sanchez Perales MC, Borrego FJ, Borrego J, Perez del Barrio P, et al. [Fistulae or catheter for

elderly who start hemodialysis without permanent vascular access?]. Nefrologia. 2005;25(3):307-14.

46. Jimenez-Almonacid P, Rio JVD, Lasala M, Rueda JA, Vorwald P, Fernandez JM, et al. [First non-autologous vascular access

for hemodialysis: PTFE fistula]. Nefrologia. 2004;24(6):559-63.

47. Hernandez-Jaras J, Garcia-Perez H, Torregrosa E, Pons R, Calvo C, Serra M, et al. [Outcome of tunneled hemodialysis

catheters as permanent vascular access]. Nefrologia. 2004;24(5):446-52.

58

48. Rodriguez JA, Ferrer E, Olmos A, Codina S, Borrellas J, Piera L. [Analysis of the survival of permanent vascular access

ports]. Nefrologia. 2001;21(3):260-73.

49. Branger B, Reboul P, Prelipcean C, Noguera ME, Cariou S, Granolleras C, et al. [Tunnelled internal jugular vein catheters

with taurolidine lock: an acceptable challenge to arterio-venous fistula in 70 years old haemodialyzed patients: a prospective pilot

study]. Nephrologie et Therapeutique. 2011;7(4):237-41.

50. Kennealey PT, Elias N, Hertl M, Ko DSC, Saidi RF, Markmann JF, et al. A prospective, randomized comparison of bovine

carotid artery and expanded polytetrafluoroethylene for permanent hemodialysis vascular access. Journal of Vascular Surgery.

2011;53(6):1640-8.

51. Diehm N, Berg JCvd, Schnyder V, Buhler J, Willenberg T, Widmer M, et al. Determinants of haemodialysis access survival.

Vasa. 2010;39(2):133-9.

52. Wasse H, Speckman RA, McClellan WM. Arteriovenous fistula use is associated with lower cardiovascular mortality

compared with catheter use among ESRD patients. Seminars in Dialysis. 2008;21(5):483-9.

53. Ko PJ, Liu YH, Hung YN, Hsieh HC. Patency rates of cuffed and noncuffed extended polytetrafluoroethylene grafts in dialysis

access: a prospective, randomized study. World Journal of Surgery. 2009;33(4):846-51.

54. Slayden GC, Spergel L, Jennings WC. Secondary arteriovenous fistulas: converting prosthetic AV grafts to autogenous

dialysis access. Seminars in Dialysis. 2008;21(5):474-82.

59

55. Ekbal NJ, Swift PA, Chalisey A, Steele M, Makanjuola D, Chemla E. Hemodialysis access-related survival and morbidity in

an elderly population in South West Thames, UK. Hemodialysis International. 2008;12 Suppl 2:S15-9.

56. Tsoulfas G, Hertl M, Ko DSC, Elias N, Delmonico FL, Romano L, et al. Long-term outcome of a cuffed expanded PTFE graft

for hemodialysis vascular access. World Journal of Surgery. 2008;32(8):1827-31.

57. Long B, Bruyere F, Lermusiaux P, Culty T, Boutin JM, Artru B, et al. [Management of perianastomotic stenoses complicating

vascular accesses for haemodialysis]. Progres en Urologie. 2008;18(7):462-9.

58. Qasaimeh GR, Qaderi SE, Omari GA, Badadweh MA. Vascular access infection among hemodialysis patients in Northern

Jordan: incidence and risk factors. Southern Medical Journal. 2008;101(5):508-12.

59. Bronder CM, Cull DL, Kuper SG, Carsten CG, Kalbaugh CA, Cass A, et al. Fistula elevation procedure: experience with 295

consecutive cases during a 7-year period. Journal of the American College of Surgeons. 2008;206(5):1076-81; discussion 81-2.

60. Torina PJ, Westheimer EF, Schanzer HR. Brachial vein transposition arteriovenous fistula: is it an acceptable option for

chronic dialysis vascular access? Journal of Vascular Access. 2008;9(1):39-44.

61. Shahnawaz, Ali S, Shahzad I, Baloch MU. Arterio venous fistula experience at a tertiary care hospital in Pakistan. Pakistan

Journal of Medical Sciences. 2013;29 (1):161-5.

62. Morale W, Patane D, Incardona C, Seminara G, Messina M, Malfa P, et al. Venae comitantes as a potential vascular resource

to create native arteriovenous fistulae. Journal of Vascular Access. 2011;12 (3):211-4.

60

63. Lee ES, Shen Q, Pitts RL, Guo M, Wu MH, Sun SC, et al. Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase

tissue inhibitors in patients are associated with arteriovenous fistula maturation. Journal of Vascular Surgery. 2011;54 (2):454-60.

64. Moussavi SR, Tofigh AM. Comparing the saphenous vein with the Gore-tex bridge fistula in thigh for chronic hemodialysis.

European Surgery - Acta Chirurgica Austriaca. 2007;39 (6):355-8.

65. Savader SJ, Haikal LC, Ehrman KO, Porter DJ, Oteham AC. Hemodialysis catheter-associated fibrin sheaths: Treatment with a

low-dose rt-PA infusion. Journal of Vascular and Interventional Radiology. 2000;11 (9):1131-6.

66. Hurlbert SN, Mattos MA, Henretta JP, Ramsey DE, Barkmeier LD, Hodgson KJ, et al. Long-term patency rates, complications

and cost-effectiveness of polytetrafluoroethylene (PTFE) grafts for hemodialysis access: A prospective study that compares Impra

versus Gore-tex grafts. Cardiovascular Surgery. 1998;6 (6):652-6.

67. McLaughlin K, Jones B, Mactier R, Porteus C. Long-term vascular access for hemodialysis using silicon dual-lumen catheters

with guidewire replacement of catheters for technique salvage. American Journal of Kidney Diseases. 1997;29 (4):553-9.

68. Ozlem N, Karakayali S, Aydin R, Tibet HB. A new method of AV fistula construction in chronic hemodialysis patients: 'Distal

snuffbox' AV fistulas. Dialysis and Transplantation. 1996;25 (2):82-6.

69. Tedoriya T, Urayama H, Katada S, Watanabe Y. A survey of vascular access for hemodialysis. Vascular Surgery. 1995;29

(2):123-7.

70. Beigi AA, Masoudpour H, Alavi M. The effect of ligation of the distal vein in snuff-box arteriovenous fistula. Saudi journal of

kidney diseases and transplantation. 2009;20(6):1110-4.

61

71. Gormus N, Ozergin U, Durgut K, Yuksek T, Solak H. Comparison of autologous basilic vein transpositions between forearm

and upper arm regions. Annals of Vascular Surgery. 2003;17(5):522-5.

72. Polo JR, Ligero JM, Diaz-Cartelle J, Garcia-Pajares R, Cervera T, Reparaz L. Randomized comparison of 6-mm straight grafts

versus 6- to 8-mm tapered grafts for brachial-axillary dialysis access. Journal of Vascular Surgery. 2004;40(2):319-24.

73. Ascher E, Gade P, Hingorani A, Mazzariol F, Gunduz Y, Fodera M, et al. Changes in the practice of angioaccess surgery:

impact of dialysis outcome and quality initiative recommendations. J Vasc Surg. 2000;31(1 Pt 1):84-92.

74. Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J. Type of vascular access and survival among incident

hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Journal of the American Society of

Nephrology : JASN. 2005;16(5):1449-55.

75. Coburn MC, Carney WI, Jr. Comparison of basilic vein and polytetrafluoroethylene for brachial arteriovenous fistula. J Vasc

Surg. 1994;20(6):896-902; discussion 3-4.

76. Haimov M, Burrows L, Schanzer H, Neff M, Baez A, Kwun K, et al. Experience with arterial substitutes in the construction of

vascular access for hemodialysis. The Journal of cardiovascular surgery. 1980;21(2):149-54.

77. Hazinedaroglu SM, Tuzuner A, Ayli D, Demirer S, Duman N, Yerdel MA. Femoral vein transposition versus femoral loop

grafts for hemodialysis: a prospective evaluation. Transplant Proc. 2004;36(1):65-7.

78. Kherlakian GM, Roedersheimer LR, Arbaugh JJ, Newmark KJ, King LR. Comparison of autogenous fistula versus expanded

polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg. 1986;152(2):238-43.

62

79. Kim YS, Yang CW, Jin DC, Ahn SJ, Chang YS, Yoon YS, et al. Comparison of peritoneal catheter survival with fistula

survival in hemodialysis. Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

1995;15(2):147-51.

80. Oliver MJ, McCann RL, Indridason OS, Butterly DW, Schwab SJ. Comparison of transposed brachiobasilic fistulas to upper

arm grafts and brachiocephalic fistulas. Kidney Int. 2001;60(4):1532-9.

81. Perera GB, Mueller MP, Kubaska SM, Wilson SE, Lawrence PF, Fujitani RM. Superiority of autogenous arteriovenous

hemodialysis access: maintenance of function with fewer secondary interventions. Ann Vasc Surg. 2004;18(1):66-73.

82. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis.

Journal of the American Society of Nephrology : JASN. 2004;15(2):477-86.

83. Ridao-Cano N, Polo JR, Polo J, Perez-Garcia R, Sanchez M, Gomez-Campdera FJ. Vascular access for dialysis in the elderly.

Blood Purif. 2002;20(6):563-8.

84. Sparks SR, VanderLinden JL, Gnanadev DA, Smith JW, Bunt TJ. Superior patency of perforating antecubital vein

arteriovenous fistulae for hemodialysis. Annals of Vascular Surgery. 1997;11 (2):165-7.

85. Tordoir JH, Kwan TS, Herman JM, Carol EJ, Jakimowicz JJ. Primary and secondary access surgery for haemodialysis with the

Brescia-Cimino fistula and the polytetrafluoroethylene (PTFE) graft. Neth J Surg. 1983;35(1):8-12.

63

86. Shemesh D, Goldin I, Zaghal I, Berlowitz D, Raveh D, Olsha O. Angioplasty with stent graft versus bare stent for recurrent

cephalic arch stenosis in autogenous arteriovenous access for hemodialysis: a prospective randomized clinical trial. Journal of

Vascular Surgery. 1531;48(6):1524-31.

87. Flu H, Breslau PJ, Straaten JMK-v, Hamming JF, Lardenoye JWH. The effect of implementation of an optimized care protocol

on the outcome of arteriovenous hemodialysis access surgery. Journal of Vascular Surgery. 2008;48(3):659-68.

88. Kakkos SK, Haddad GK, Haddad RK, Scully MM. Effectiveness of a new tunneled catheter in preventing catheter

malfunction: a comparative study. Journal of Vascular & Interventional Radiology. 2008;19(7):1018-26.

89. Wu CC, Wen SC. Cutting balloon angioplasty for resistant venous stenoses of dialysis access: immediate and patency results.

Catheterization & Cardiovascular Interventions. 2008;71(2):250-4.

90. Kakkos SK, Andrzejewski T, Haddad JA, Haddad GK, Reddy DJ, Nypaver TJ, et al. Equivalent secondary patency rates of

upper extremity Vectra Vascular Access Grafts and transposed brachial-basilic fistulas with aggressive access surveillance and

endovascular treatment. Journal of Vascular Surgery. 2008;47(2):407-14.

91. Jean-Baptiste E, Hassen-Khodja R, Haudebourg P, Declemy S, Batt M, Bouillanne PJ. Axillary loop grafts for hemodialysis

access: midterm results from a single-center study. Journal of Vascular Surgery. 2008;47(1):138-43.

92. Schild AF, Perez EA, Gillaspie E, Patel AR, Noicely K, Baltodano N. Use of the Vectra polyetherurethaneurea graft for

dialysis access in HIV-positive patients with end-stage renal disease. Vascular & Endovascular Surgery. 2007;41(6):506-8.

64

93. Moossavi S, Regan JD, Pierson ED, Kasey JM, Tuttle AB, Vachharajani TJ, et al. Non-surgical salvage of thrombosed arterio-

venous fistulae: a case series and review of the literature. Seminars in Dialysis. 2007;20(5):459-64.

94. Woo K, Farber A, Doros G, Killeen K, Kohanzadeh S. Evaluation of the efficacy of the transposed upper arm arteriovenous

fistula: a single institutional review of 190 basilic and cephalic vein transposition procedures. Journal of Vascular Surgery.

2007;46(1):94-9; discussion 100.

95. Kayacioglu I, Baysal A, Ates M, Vural U, Balci AY, Saskin H, et al. The effect of the keyhole technique on diabetic patients

undergoing autologous brachiobasilic transposition of an arteriovenous fistula. Heart Surgery Forum. 2007;10(2):E147-52.

96. Lee T, Barker J, Allon M. Comparison of survival of upper arm arteriovenous fistulas and grafts after failed forearm fistula. J

Am Soc Nephrol. 2007;18(6):1936-41.

97. Shemesh D, Goldin I, Berelowitz D, Zaghal I, Zigelman C, Olsha O. Blood flow volume changes in the maturing

arteriovenous access for hemodialysis. Ultrasound in Medicine & Biology. 2007;33(5):727-33.

98. Basaran O, Atac FB, Karakayali F, Aliosmanoglu I, Yagmurdur MC, Ozdemir FN, et al. Endothelial nitric oxide synthase gene

intron 4 (VNTR) polymorphism and vascular access graft thrombosis. Journal of Investigative Surgery. 2007;20(1):49-53.

99. Korten E, Toonder IM, Schrama YC, Hop WCJ, Ham ACvd, Wittens CHA. Dialysis fistulae patency and preoperative

diameter ultrasound measurements. European Journal of Vascular & Endovascular Surgery. 2007;33(4):467-71.

100. Yilmaz M, Senkaya I, Saba D, Bicer M. Long-term outcomes of basilic vein transposition fistula for hemodialysis. Vasa.

2007;36(1):29-32.

65

101. Mitchell D, Krishnasami Z, Young CJ, Allon M. Arteriovenous access outcomes in haemodialysis patients with HIV infection.

Nephrology Dialysis Transplantation. 2007;22(2):465-70.

102. Inrig JK, Reed SD, Szczech LA, Engemann JJ, Friedman JY, Corey GR, et al. Relationship between clinical outcomes and

vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Clinical Journal of The American Society

of Nephrology: CJASN. 2006;1(3):518-24.

103. Karakayali F, Basaran O, Ekici Y, Budakoglu I, Aytekin C, Boyvat F, et al. Effect of secondary interventions on patency of

vascular access sites for hemodialysis. European Journal of Vascular & Endovascular Surgery. 2006;32(6):701-9.

104. Sayed HFE, Mendoza B, Meier GH, LeSar CJ, DeMasi RJ, Glickman MH, et al. Utility of basilic vein transposition for

dialysis access. Vascular. 2005;13(5):268-74.

105. Fitzgerald JT, Schanzer A, McVicar JP, Chin AI, Perez RV, Troppmann C. Upper arm arteriovenous fistula versus forearm

looped arteriovenous graft for hemodialysis access: a comparative analysis. Annals of Vascular Surgery. 2005;19(6):843-50.

106. Modarai B, Dasgupta P, Taylor J, Koffman G, Khan MS. Follow-up of polytetrafluoroethylene arteriovenous fistulae for

haemodialysis. International Journal of Clinical Practice. 2005;59(9):1005-7.

107. Kizilisik AT, Kim SB, Nylander WA, Shaffer D. Improvements in dialysis access survival with increasing use of arteriovenous

fistulas in a Veterans Administration medical center. American Journal of Surgery. 2004;188(5):614-6.

108. Ko PJ, Hsieh HC, Chu JJ, Lin PJ, Liu YH. Patency rates and complications of Exxcel yarn-wrapped polytetrafluoroethylene

grafts versus Gore-tex stretch polytetrafluoroethylene grafts: a prospective study. Surgery Today. 2004;34(5):409-12.

66

109. Fitzgerald JT, Schanzer A, Chin AI, McVicar JP, Perez RV, Troppmann C. Outcomes of upper arm arteriovenous fistulas for

maintenance hemodialysis access. Archives of Surgery. 2004;139(2):201-8.

110. Mazzoni G, Frattarelli D, Iafrancesco D, Vagni V, Morosetti M, Farao RM. [Arteriovenous brachio-basilic fistula as

hemodialysis port. Original technique and long term results]. Giornale di Chirurgia. 2003;24(10):371-6.

111. Senkaya I, Aytac II, Eercan AK, Aliosman A, Percin B. The graft selection for haemodialysis. Vasa. 2003;32(4):209-13.

112. Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with mortality outcomes in elderly

Medicare ESRD patients. American Journal of Kidney Diseases. 2003;42(5):1013-9.

113. Shenoy S, Miller A, Petersen F, Kirsch WM, Konkin T, Kim P, et al. A multicenter study of permanent hemodialysis access

patency: beneficial effect of clipped vascular anastomotic technique. Journal of Vascular Surgery. 2003;38(2):229-35.

114. Bruns SD, Jennings WC. Proximal radial artery as inflow site for native arteriovenous fistula. Journal of the American College

of Surgeons. 2003;197(1):58-63.

115. Wiese P, Blume J, Mueller HJ, Renner H, Nonnast D, Barbara. Clinical and Doppler ultrasonography data of a polyurethane

vascular access graft for haemodialysis: a prospective study. Nephrology Dialysis Transplantation. 2003;18(7):1397-400.

116. Baldrati L, Pascalis AD, Giudicissi A, Docci D, Neri L, Feletti C. [Pre-dialysis arteriovenous fistula results in better patency

rate]. Giornale Italiano di Nefrologia. 2003;20(2):166-9.

117. Hossny A. Brachiobasilic arteriovenous fistula: different surgical techniques and their effects on fistula patency and dialysis-

related complications. Journal of Vascular Surgery. 2003;37(4):821-6.

67

118. Dalman RL, Harris EJ, Jr, Victor BJ, Coogan SM. Transition to all-autogenous hemodialysis access: the role of preoperative

vein mapping. Annals of Vascular Surgery. 2002;16(5):624-30.

119. Sorom AJ, Hughes CB, McCarthy JT, Jenson BM, Prieto M, Panneton JM, et al. Prospective, randomized evaluation of a

cuffed expanded polytetrafluoroethylene graft for hemodialysis vascular access. Surgery. 2002;132(2):135-40.

120. Ascher E, Hingoran A, Gunduz Y, Yorkovich Y, Ward M, Miranda J, et al. The value and limitations of the arm cephalic and

basilic vein for arteriovenous access. Ann Vasc Surg. 2001;15(1):89-97.

121. Wolowczyk L, Williams AJ, Donovan KL, Gibbons CP. The snuffbox arteriovenous fistula for vascular access. European

Journal of Vascular & Endovascular Surgery. 2000;19(1):70-6.

122. Taylor SM, Eaves GL, Weatherford DA, McAlhany JC, Jr, Russell HE, et al. Results and complications of arteriovenous

access dialysis grafts in the lower extremity: a five year review. American Surgeon. 1996;62(3):188-91.

123. Helling TS, Nelson PW, Shelton L. A prospective evaluation of plasma-TFE and expanded PTFE grafts for routine and early

use as vascular access during hemodialysis. Annals of Surgery. 1992;216(5):596-9.

124. Nannery WM, Stoldt HS, Fares LG, nd. Hemodialysis access operations performed upon patients with human

immunodeficiency virus. Surgery, Gynecology & Obstetrics. 1991;173(5):387-90.

125. Donnelly PK, Hoenich NA, Lennard TW, Proud G, Taylor RM. Surgical management of long-term central venous access in

uraemic patients. Nephrology Dialysis Transplantation. 1988;3(1):57-65.

68

126. Rizzuti RP, Hale JC, Burkart TE. Extended patency of expanded polytetrafluoroethylene grafts for vascular access using

optimal configuration and revisions. Surgery, Gynecology & Obstetrics. 1988;166(1):23-7.

127. Elwakeel H, Khafagy T, Regal S, Saad E. Prosthetic axillary-axillary arm loop arteriovenous graft for hemodialysis.

International Angiology. 2013;32(6):589-92.

128. Nadeau-Fredette AC, Goupil R, Montreuil B, Carignan A, Leblanc M. Arteriovenous fistula for the 80 years and older patients

on hemodialysis: is it worth it? Hemodialysis International. 2013;17(4):594-601.

129. Scarritt T, Paragone CM, Gorman RBO, Kyriazis DK, Maltese C, Rostas JW, et al. Traditional versus early-access grafts for

hemodialysis access: a single-institution comparative study. American Surgeon. 2014;80(2):155-8.

130. Hruby Z, Stanek-Piotrowska M, Turek J, Witkiewicz W, Jonkisz A, Konieczny A, et al. The clinicopathological determinants

of native arteriovenous fistula failure in patients on maintenance hemodialysis. Advances in Clinical & Experimental Medicine.

2013;22(4):495-500.

131. Kanko M, Sen C, Yavuz S, Unal C, Aksoy A, Berki T. Evaluation of arteriovenous fistulas made with the diamond-shaped

anastomosis technique. Medical Science Monitor. 2012;18(9):MT67-70.

132. Gage SM, Katzman HE, Ross JR, Hohmann SE, Sharpe CA, Butterly DW, et al. Multi-center experience of 164 consecutive

Hemodialysis Reliable Outflow [HeRO] graft implants for hemodialysis treatment. European Journal of Vascular & Endovascular

Surgery. 2012;44(1):93-9.

69

133. Basel H, Ekim H, Odabasi D, Kiymaz A, Aydin C, Dostbil A. Basilic vein transposition fistulas versus prosthetic bridge grafts

in patients with end-stage renal failure. Annals of Vascular Surgery. 2011;25(5):634-9.

134. Walker SR. U Clips for arteriovenous anastomosis: a pilot, randomized study. ANZ Journal of Surgery. 2012;82(9):630-2.

135. Huddam B, Azak A, Kocak G, Ortabozkoyun L, Duranay M. The efficacy of prophylactic antibiotics administration prior to

insertion of tunneled catheter in hemodialysis patients. Renal Failure. 2012;34(8):998-1001.

136. Woo K, Yao J, Selevan D, Hye RJ. Influence of vascular access type on sex and ethnicity-related mortality in hemodialysis-

dependent patients. Perm J. 2012;16(2):4-9.

137. Lukowsky LR, Kheifets L, Arah OA, Nissenson AR, Kalantar-Zadeh K. Patterns and predictors of early mortality in incident

hemodialysis patients: new insights. American Journal of Nephrology. 2012;35(6):548-58.

138. Solid CA, Carlin C. Timing of arteriovenous fistula placement and Medicare costs during dialysis initiation. American Journal

of Nephrology. 2012;35(6):498-508.

139. Matsumoto H, Yamamoto E, Kamiya C, Miura E, Kitaoka T, Suzuki J, et al. Early use of brachial-basilic arteriovenous fistula.

Journal of Vascular Access. 2012;13(2):251-5.

140. DeSilva RN, Sandhu GS, Garg J, Goldfarb-Rumyantzev AS. Association between initial type of hemodialysis access used in

the elderly and mortality. Hemodialysis International. 2012;16(2):233-41.

141. Vahedian J, Jalayifar AM, Keramati MR, Nabavizadeh F, Vahedian M. Primary success of bifurcated vein patch arteriovenous

fistula and Brescia-Cimino methods. Iranian journal of Kidney Diseases. 2012;6(2):124-8.

70

142. Jackson RS, Sidawy AN, Amdur RL, Khetarpal A, Macsata RA. Angiotensin receptor blockers and antiplatelet agents are

associated with improved primary patency after arteriovenous hemodialysis access placement. Journal of Vascular Surgery.

2011;54(6):1706-12.

143. Chan KE, Pflederer TA, Steele DJR, Lilly MP, Ikizler TA, Maddux FW, et al. Access survival amongst hemodialysis patients

referred for preventive angiography and percutaneous transluminal angioplasty. Clinical Journal of The American Society of

Nephrology: CJASN. 2011;6(11):2669-80.

144. Conte MS, Nugent HM, Gaccione P, Roy-Chaudhury P, Lawson JH. Influence of diabetes and perivascular allogeneic

endothelial cell implants on arteriovenous fistula remodeling. Journal of Vascular Surgery. 2011;54(5):1383-9.

145. Powell S, Chan TY, Bhat R, Lam K, Narlawar RS, Cullen N, et al. A retrospective comparative study of tunneled

haemodialysis catheters inserted through occluded or collateral veins versus conventional methods. Cardiovascular & Interventional

Radiology. 2010;33(4):744-50.

146. Karakayali F, Ekici Y, Gorur SK, Arat Z, Boyvat F, Karakayali H, et al. The value of preoperative vascular imaging in the

selection and success of hemodialysis access. Annals of Vascular Surgery. 2007;21(4):481-9.

147. Hamida FB, Hibik SM, Karoui C, Abderrahim E, Kaaroud H, Beji S, et al. [Indications, complications and cost of internal

jugular catheters in hemodialysed patients: study of 533 cases]. Tunisie Medicale. 2005;83(9):519-23.

148. Cetinkaya R, Odabas AR, Unlu Y, Selcuk Y, Ates A, Ceviz M. Using cuffed and tunnelled central venous catheters as

permanent vascular access for hemodialysis: a prospective study. Renal Failure. 2003;25(3):431-8.

71

149. Gorski TF, Gorski YC, Muney J. Complications of hemodialysis access in HIV-positive patients. American Surgeon.

2002;68(12):1104-6.

150. Ravani P, Marcelli D, Malberti F. Vascular access surgery managed by renal physicians: the choice of native arteriovenous

fistulas for hemodialysis. American Journal of Kidney Diseases. 2002;40(6):1264-76.

151. Bacchini G, Vecchio LD, Andrulli S, Pontoriero G, Locatelli F. Survival of prosthetic grafts of different materials after

impairment of a native arteriovenous fistula in hemodialysis patients. ASAIO Journal. 2001;47(1):30-3.

152. Friedman AL, Walworth C, Meehan C, Wander H, Shemin D, DeSoi W, et al. First hemodialysis access selection varies with

patient acuity. Advances in Renal Replacement Therapy. 2000;7(4 Suppl 1):S4-10.

153. Leapman SB, Boyle M, Pescovitz MD, Milgrom ML, Jindal RM, Filo RS. The arteriovenous fistula for hemodialysis access:

gold standard or archaic relic? American Surgeon. 1996;62(8):652-6; discussion 6-7.

154. Cohen MA, Kumpe DA, Durham JD, Zwerdlinger SC. Improved treatment of thrombosed hemodialysis access sites with

thrombolysis and angioplasty. Kidney International. 1994;46(5):1375-80.

155. Viron B, Lukacs B, Michel C, Thibault P, Mignon F. [Prosthesis without puncture, 3d generation of vascular access for

hemodialysis: a study of Hemasite in 10 patients]. Nephrologie. 1987;8(5):261-6.

156. Weale AR, Bevis P, Neary WD, Boyes S, Morgan JD, Lear PA, et al. Radiocephalic and brachiocephalic arteriovenous fistula

outcomes in the elderly. Journal of Vascular Surgery. 2008;47 (1):144-50.

72

157. Gargiulo M, Freyrie A, Faggioli GL, Tarantini S, Mosconi G, Santoro A, et al. Humeral-cephalic graft fistula in patients

requiring hemodialysis. Giornale Italiano di Chirurgia Vascolare. 1999;6 (4):269-79.

158. Mortazavi M, Alsaeidi S, Sobhani R, Salimic F, Atapour A, Sharif N, et al. Successful prevention of tunneled, central catheter

infection by antibiotic lock therapy using cefotaxime. Journal of Research in Medical Sciences. 2011;16(3):303-9.

159. Gibson KD, Gillen DL, Caps MT, Kohler TR, Sherrard DJ, Stehman-Breen CO. Vascular access survival and incidence of

revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal

Data System Dialysis Morbidity and Mortality Study. J Vasc Surg. 2001;34(4):694-700.

160. Taylor B, Sigley RD, May KJ. Fate of infected and eroded hemodialysis grafts and autogenous fistulas. Am J Surg.

1993;165(5):632-6.

161. Morosetti M, Cipriani S, Dominijanni S, Pisani G, Frattarelli D, Bruno F. Basilic vein transposition versus biosynthetic

prosthesis as vascular access for hemodialysis. J Vasc Surg. 2011;54(6):1713-9.

162. Chen HY, Chiu YL, Chuang YF, Hsu SP, Pai MF, Lai CF, et al. Association of low serum fetuin A levels with poor

arteriovenous access patency in patients undergoing maintenance hemodialysis. American Journal of Kidney Diseases.

2010;56(4):720-7.

163. Gonzalez E, Kashuk JL, Moore EE, Linas S, Sauaia A. Two-stage brachial-basilic transposition fistula provides superior

patency rates for dialysis access in a safety-net population. Surgery. 2010;148(4):687-93; discussion 93-4.

73

164. Dember LM, Beck GJ, Allon M, Delmez JA, Dixon BS, Greenberg A, et al. Effect of clopidogrel on early failure of

arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA. 2008;299(18):2164-71.

165. Louridas G, Botha JR, Levien L, Milne FJ, Meyers AM, Myburgh JA. Vascular access for haemodialysis--experience at

Johannesburg Hospital. South African Medical Journal Suid-Afrikaanse Tydskrif Vir Geneeskunde. 1984;66(17):637-40.

166. Foley RN, Chen SC, Collins AJ. Hemodialysis access at initiation in the United States, 2005 to 2007: still "catheter first".

Hemodialysis International. 2009;13(4):533-42.

167. Salman L, Alex M, Unger SW, Contreras G, Lenz O, Asif A. Secondary autogenous arteriovenous fistulas in the "fistula first"

era: results of a longterm prospective study. Journal of the American College of Surgeons. 2009;209(1):100-5.

168. Bradbury BD, Chen F, Furniss A, Pisoni RL, Keen M, Mapes D, et al. Conversion of vascular access type among incident

hemodialysis patients: description and association with mortality. American Journal of Kidney Diseases. 2009;53(5):804-14.

169. Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, Krishnan M, et al. Facility hemodialysis vascular access use and

mortality in countries participating in DOPPS: an instrumental variable analysis. American Journal of Kidney Diseases.

2009;53(3):475-91.

170. Bhomi KK, Shrestha S, Bhattachan CL. Role of systemic anticoagulation in patients undergoing vascular access surgery.

Nepal Medical College Journal: NMCJ. 2008;10(4):222-4.

171. Grubbs V, Wasse H, Vittinghoff E, Grimes BA, Johansen KL. Health status as a potential mediator of the association between

hemodialysis vascular access and mortality. Nephrol Dial Transplant. 2014;29(4):892-8.

74

172. Jemcov TK. Morphologic and functional vessels characteristics assessed by ultrasonography for prediction of radiocephalic

fistula maturation. Journal of Vascular Access. 2013;14(4):356-63.

173. Alhassan SU, Adamu B, Abdu A, Aji SA. Outcome and complications of permanent hemodialysis vascular access in

Nigerians: a single centre experience. Annals of African Medicine. 2013;12(2):127-30.

174. Ilhan G, Esi E, Bozok S, Yurekli I, Ozpak B, Ozelci A, et al. The clinical utility of vascular mapping with Doppler ultrasound

prior to arteriovenous fistula construction for hemodialysis access. Journal of Vascular Access. 2013;14(1):83-8.

175. Manson RJ, Ebner A, Gallo S, Chemla E, Mantell M, Deaton D, et al. Arteriovenous fistula creation using the Optiflow

vascular anastomosis device: a first in man pilot study. Seminars in Dialysis. 2013;26(1):97-9.

176. Wongkonkitsin N, Prasertcharoensuk S. Patency of vascular accesses for Thai hemodialysis patients. J Med Assoc Thai.

2014;97(3):317-21.

177. Watorek E, Golebiowski T, Kusztal M, Letachowicz K, Letachowicz W, Augustyniak Bartosik H, et al. Creation of

arteriovenous fistulae for hemodialysis in octogenarians. Hemodial. 2014;18(1):113-7.

178. Wetzig GA, Gough IR, Furnival CM. One hundred cases of arteriovenous fistula for haemodialysis access: the effect of

cigarette smoking on patency. Australian & New Zealand Journal of Surgery. 1985;55(6):551-4.

179. Hart D, Gooden C, Cummings LS, Wible BC, Borsa J, Randall H. Modification of the HeRO graft allowing earlier cannulation

and reduction in catheter dependent days in patients with end stage renal disease: A single center retrospective review. The Scientific

World Journal. 2014;2014(318629).

75

180. Persic V, Buturovic-Ponikvar J, Arnol M, Ponikvar R. Outcomes of native arteriovenous fistula in hemodialysis patients over

65 years of age. Nephrology Dialysis Transplantation. 2013;Conference: 50th ERA-EDTA Congress Istanbul Turkey. Conference

Start: 20130518 Conference End: 20130521. Conference Publication: (var.pagings). 28:i235.

181. Prischl FC, Kirchgatterer A, Brandstatter E, Wallner M, Baldinger C, Roithinger FX, et al. Parameters of prognostic relevance

to the patency of vascular access in hemodialysis patients. J Am Soc Nephrol. 1995;6(6):1613-8.

182. Kaufman JL, Garb JL, Berman JA, Rhee SW, Norris MA, Friedmann P. A prospective comparison of two expanded

polytetrafluoroethylene grafts for linear forearm hemodialysis access: does the manufacturer matter? J Am Coll Surg. 1997;185(1):74-

9.

183. Lok CE, Oliver MJ, Su J, Bhola C, Hannigan N, Jassal SV. Arteriovenous fistula outcomes in the era of the elderly dialysis

population. Kidney Int. 2005;67(6):2462-9.

184. Vaux E, King J, Lloyd S, Moore J, Bailey L, Reading I, et al. Effect of buttonhole cannulation with a polycarbonate PEG on

in-center hemodialysis fistula outcomes: a randomized controlled trial. Am J Kidney Dis. 2013;62(1):81-8.

185. Bender MH, Bruyninckx CM, Gerlag PG. The Gracz arteriovenous fistula evaluated. Results of the brachiocephalic elbow

fistula in haemodialysis angio-access. European journal of vascular and endovascular surgery : the official journal of the European

Society for Vascular Surgery. 1995;10(3):294-7.

186. Yasuhara H, Shigematsu H, Muto T. Results of arteriovenous fistula revision in the forearm. Am J Surg. 1997;174(1):83-6.

76

187. Wang SS, Chu SH. Clinical use of omniflow vascular graft as arteriovenous bridging graft for hemodialysis. Artif Organs.

1996;20(12):1278-81.

188. Kalman PG, Pope M, Bhola C, Richardson R, Sniderman KW. A practical approach to vascular access for hemodialysis and

predictors of success. J Vasc Surg. 1999;30(4):727-33.

189. Elcheroth J, de Pauw L, Kinnaert P. Elbow arteriovenous fistulas for chronic haemodialysis. Br J Surg. 1994;81(7):982-4.

190. Simoni G, Bonalumi U, Civalleri D, Decian F, Bartoli FG. End-to-end arteriovenous fistula for chronic haemodialysis: 11

years' experience. Cardiovascular surgery. 1994;2(1):63-6.

191. Rubens F, Wellington JL. Brachiocephalic fistula: a useful alternative for vascular access in chronic hemodialysis.

Cardiovascular surgery. 1993;1(2):128-30.

192. Burt CG, Little JA, Mosquera DA. The effect of age on radiocephalic fistula patency. J Vasc Access. 2001;2(3):110-3.

193. Golledge J, Smith CJ, Emery J, Farrington K, Thompson HH. Outcome of primary radiocephalic fistula for haemodialysis. Br

J Surg. 1999;86(2):211-6.

194. Lemson MS, Tordoir JH, van Det RJ, Welten RJ, Burger H, Estourgie RJ, et al. Effects of a venous cuff at the venous

anastomosis of polytetrafluoroethylene grafts for hemodialysis vascular access. J Vasc Surg. 2000;32(6):1155-63.

195. Curi MA, Pappas PJ, Silva MB, Jr., Patel S, Padberg FT, Jr., Jamil Z, et al. Hemodialysis access: influence of the human

immunodeficiency virus on patency and infection rates. J Vasc Surg. 1999;29(4):608-16.

77

196. Munda R, First MR, Alexander JW, Linnemann CC, Jr., Fidler JP, Kittur D. Polytetrafluoroethylene graft survival in

hemodialysis. Jama. 1983;249(2):219-22.

197. Silva MB, Jr., Hobson RW, 2nd, Pappas PJ, Haser PB, Araki CT, Goldberg MC, et al. Vein transposition in the forearm for

autogenous hemodialysis access. J Vasc Surg. 1997;26(6):981-6; discussion 7-8.

198. Hakaim AG, Scott TE. Durability of early prosthetic dialysis graft cannulation: results of a prospective, nonrandomized

clinical trial. J Vasc Surg. 1997;25(6):1002-5; discussion 5-6.

199. Bone GE, Pomajzl MJ. Prospective comparison of polytetrafluoroethylene and bovine grafts for dialysis. The Journal of

surgical research. 1980;29(3):223-7.

200. Hibberd AD. Brachiobasilic fistula with autogenous basilic vein: surgical technique and pilot study. The Australian and New

Zealand journal of surgery. 1991;61(8):631-5.

78